Journal of pain & palliative care pharmacotherapy
-
J Pain Palliat Care Pharmacother · Jan 2008
The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT).
Americans continue to spend millions of dollars annually on glucosamine and chondroitin for symptoms of osteoarthritis. These agents are classified as dietary supplements, not as drugs, per se. Therefore, they do not meet the requirements of the FDA to be classified as drugs. ⋯ For a subset of participants with moderate-to-severe pain, glucosamine combined with chondroitin sulfate provided statistically significant pain relief compared with placebo, about 79% had a 20% or greater reduction in pain versus about 54% for placebo. According to the researchers, because of the small size of this subgroup these findings should be considered preliminary and need to be confirmed in further studies. For participants in the mild pain subset, glucosamine and chondroitin sulfate together or alone did not provide statistically significant pain relief.
-
J Pain Palliat Care Pharmacother · Jan 2008
Biofeedback in pain management: Bier blocks for complex regional pain syndrome.
This feature presents information for patients in a question and answer format. It is written to simulate actual questions that many pain patients ask and to provide answers in a context and language that most pain patients will comprehend. Issues addressed in this issue are the role of the biofeedback in pain management and Bier blocks for complex regional pain syndrome.
-
J Pain Palliat Care Pharmacother · Jan 2008
Awareness and action for eliminating health care disparities in pain care: Web-based resources.
Evidence shows that disparities in pain care exist, and this problem spans across all health care settings. Health care disparities are complex, and stem from the health system climate, limitations imposed by laws and regulations, and discriminatory practices that are deep seated in biases, stereotypes, and uncertainties surrounding communication and decision-making processes. ⋯ Web sites for federal agencies, private foundations, and professional and consumer-oriented organizations provide useful information on disparities related to age, race, ethnicity, geography, socioeconomic status, and specific populations. The contents of 10 Web sites are examined for resources to assist health professionals and consumers in better understanding health and pain disparities and ways to overcome them in practice.
-
On September 13, 2007, the United States Food and Drug Administration posted a safety alert for fentanyl buccal tablets (Fentora). The announcement and hyperlinks to the Dear Doctor and Dear Healthcare Professional Letters that were distributed by the sponsor are presented.
-
The various institutes and offices of the National Institutes of Health (NIH) publish a range of public information articles on pain and its management. The National Institute of Neurological Disorders and Stroke (NINDS) updated its public information on chronic pain last august. That information is available to the public and clinicians will find it useful to learn what the information to which their patients have ready access via the World Wide Web. The most recent NINDS description of chronic pain is presented.